Table 4 Novel agents in use or trials in... | American Society of Hematology

Table 4

Novel agents in use or trials in PTCL

Type of agent	Name	Description	Disease(s)	Status
Antifolates	Pralatrexate	10-Deazaminopoterin	PTCL, CTCL	Approved for PTCL
Conjugates	LMB-2	Anti-Tac) anti-CD25 fused to Pseudomonas toxin	CTCL, PTCL (especially ATLL)	Phase 2
Conjugates	Denileukin diftitox	IL-2 targeting domain fused with diphtheria toxin	CTCL, PTCL	Approved for CTCL
	Brentuximab vedotin	CD30 antibody conjugated to monomethylauristan-E	CD30⁺ T-cell lymphoma	Phase 2
HDAC inhibitors	Belinostat	PXD101	CTCL, PTCL	Phase 2
	Panobinostat	LBH589	CTCL, ATL	Phase 2
	Romidepsin	Depsipeptide	CTCL, PTCL	Approved for CTCL
	Vorinostat	Suberoylanilide hydroxamic acid	CTCL	Approved for CTCL
Immunomodulatory agents	Lenalidomide	Derivative of thalidomide	PTCL, CTCL	Phase 2
Immunosuppressive agents	Cyclosporine	Inhibitor of the NF-AT transcription complex	AITL	Phase 2
Monoclonal antibodies	Alemtuzumab	Anti-CD52	PTCL	Phase 3
	Bevacizumab	Anti-VEGF	PTCL (especially AITL), NK-cell	Phase 2
	Iratumumab	Anti-CD30	CD30⁺ ALCL	Phase 1/2
	KW-0761	Anti-CCR4	ATLL, PTCL	Phase 2
	SGN-30	Anti-CD30	CD30⁺ ALCL	Phase 2
	Siplizumab	Anti-CD2	PTCL, NK-cell, ATLL	Phase 1
	Zanolimumab	Anti-CD4	CTCL, PTCL	Phase 2
Nucleoside analogs	Cladribine	Purine nucleoside analog	PTCL	Phase 4
	Clofarabine	Purine nucleoside analog	PTCL, NK-cell	Phase 1/2
	Fludarabine	Purine nucleoside analog	PTCL, CTCL	Phase 2
	Forodesine	Metabolic enzyme inhibitor	PTCL, CTCL	Phase 2
	Gemcitabine	Pyrimidine nucleoside analog	PTCL	Phase 2
	Nelarabine	Purine nucleoside analog	T-ALL, T-NHL	Phase 2
	Pentostatin	Metabolic enzyme inhibitor	PTCL	Phase 2
Proteasome inhibitors	Bortezomib	Proteasome inhibitor	CTCL	Phase 2
Signaling inhibitors	Enzastaurin	Selective inhibitor of protein kinase C	PTCL, CTCL	Phase 2
Signaling inhibitors	R788	Syk inhibitor	PTCL	Phase 2

Type of agent	Name	Description	Disease(s)	Status
Antifolates	Pralatrexate	10-Deazaminopoterin	PTCL, CTCL	Approved for PTCL
Conjugates	LMB-2	Anti-Tac) anti-CD25 fused to Pseudomonas toxin	CTCL, PTCL (especially ATLL)	Phase 2
Conjugates	Denileukin diftitox	IL-2 targeting domain fused with diphtheria toxin	CTCL, PTCL	Approved for CTCL
	Brentuximab vedotin	CD30 antibody conjugated to monomethylauristan-E	CD30⁺ T-cell lymphoma	Phase 2
HDAC inhibitors	Belinostat	PXD101	CTCL, PTCL	Phase 2
	Panobinostat	LBH589	CTCL, ATL	Phase 2
	Romidepsin	Depsipeptide	CTCL, PTCL	Approved for CTCL
	Vorinostat	Suberoylanilide hydroxamic acid	CTCL	Approved for CTCL
Immunomodulatory agents	Lenalidomide	Derivative of thalidomide	PTCL, CTCL	Phase 2
Immunosuppressive agents	Cyclosporine	Inhibitor of the NF-AT transcription complex	AITL	Phase 2
Monoclonal antibodies	Alemtuzumab	Anti-CD52	PTCL	Phase 3
	Bevacizumab	Anti-VEGF	PTCL (especially AITL), NK-cell	Phase 2
	Iratumumab	Anti-CD30	CD30⁺ ALCL	Phase 1/2
	KW-0761	Anti-CCR4	ATLL, PTCL	Phase 2
	SGN-30	Anti-CD30	CD30⁺ ALCL	Phase 2
	Siplizumab	Anti-CD2	PTCL, NK-cell, ATLL	Phase 1
	Zanolimumab	Anti-CD4	CTCL, PTCL	Phase 2
Nucleoside analogs	Cladribine	Purine nucleoside analog	PTCL	Phase 4
	Clofarabine	Purine nucleoside analog	PTCL, NK-cell	Phase 1/2
	Fludarabine	Purine nucleoside analog	PTCL, CTCL	Phase 2
	Forodesine	Metabolic enzyme inhibitor	PTCL, CTCL	Phase 2
	Gemcitabine	Pyrimidine nucleoside analog	PTCL	Phase 2
	Nelarabine	Purine nucleoside analog	T-ALL, T-NHL	Phase 2
	Pentostatin	Metabolic enzyme inhibitor	PTCL	Phase 2
Proteasome inhibitors	Bortezomib	Proteasome inhibitor	CTCL	Phase 2
Signaling inhibitors	Enzastaurin	Selective inhibitor of protein kinase C	PTCL, CTCL	Phase 2
Signaling inhibitors	R788	Syk inhibitor	PTCL	Phase 2

There are several other experimental agents in various stage clinical trials for T-cell lymphoma.

PTCL indicates peripheral T-cell lymphoma; CTCL, cutaneous T-cell lymphoma; ATLL, adult T-cell lymphoma; HDAC, histone deacetylase; NF-AT, nuclear factor of activated T cell; AITL, angioimmunoblastic T-cell lymphoma; NK, natural killer; ALCL, anaplastic large cell lymphoma; T-ALL, T-cell acute lymphoblastic leukemia; and T-NHL, T-cell non-Hodgkin lymphoma.

View Large

This Feature Is Available To Subscribers Only